Sunil Shah
CEO & Co-Founder @ O2h Ventures
Cambridge, United States
Sunil Shah is a seed investor at O2h Ventures in Cambridge focused on Health Care and Biotechnology. Sunil Shah is the CEO and Co-Founder of o2h group. He previously worked at India-UK Cancer Research Initiative (CRUK-DBT) as an Advisory Panel Member. Sunil Shah attended the University of Cambridge.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 82%
Last updated:
For AI agents: llms.txt
Industries Sunil Shah invests in
Stages Sunil Shah invests in
Countries Sunil Shah invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 9 (82%)
- Biotechnology 7 (64%)
- Biopharma 5 (45%)
- Pharmaceutical 4 (36%)
- Health Diagnostics 3 (27%)
Stage
- Seed 6 (55%)
- Series A 2 (18%)
- Pre-Seed 1 (9%)
- Post-IPO Equity 1 (9%)
- Venture - Series Unknown 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Stingray Bio is ab biotechnology company that targets LMTK3 kinase to develop precision therapeutics for treating cancer. | Seed / Apr 08, 2021 | ||
| Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines. | Seed / Jan 22, 2021 | ||
| Tay Therapeutics is a drug discovery company that develops the next generation of topical and oral therapies for inflammatory conditions. | Pre-Seed / Nov 27, 2020 | ||
| Cortirio is a portable diagnosis of brain injuries. Traumatic brain injury is the leading cause of death and disability among the under 40s. Our portable scanners can be used at the point of care to rapidly diagnose and monitor traumatic brain injuries. Saving time saves brain function, preventing disability and death. | Seed / Oct 15, 2020 | ||
| Aiming to make rehabilitation more autonomous, enjoyable and accessible to stroke victims. | Seed / Feb 15, 2020 | ||
| Small Pharma applies expert intellectual property design to guide academic discovery to commercial product. We operate a scalable model of outsourced drug development. We assemble specific expert teams to design and execute development programs with demonstrated track-records in all disciplines essential to their success. | Venture - Series Unknown / Jul 18, 2019 | ||
| Metrion Biosciences is a Contract Research Organization (CRO) that is located in the world renowned Cambridge biocluster. | Series A / Apr 01, 2019 | ||
| Deepmatter Group Plc is a big data and analysis company which has built a platform - DigitalGlassware™, focused on enabling reproducibility in chemistry. It continues to develop this software to deliver applications resulting in new optimised chemicals, materials and formulations in such commercially significant areas as pharmaceutical research,fine chemicals, scientific publications and teaching. Deepmatter is at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine, the Chemputer™. | Post-IPO Equity / Mar 18, 2019 | ||
| Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of theretina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants.Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics.During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies.About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease.About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset.The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO.*source: https://nei.nih.gov/health/diabetic/retinopathy | $1.9M / Series A / Jan 03, 2019 | ||
| Stemnovate is a unique, innovative drug development platforms enable the right patients to be targeted with the right treatments, at the right time. | Seed / May 25, 2018 | ||
| See all 11 investments → | |||
Co-Investors
About O2h Ventures
Investment firm which in backing biotech, offering investors the opportunity to back promising medical innovations via the EIS and SEIS.
O2h Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sunil Shah
CEO & Co-Founder
|
|||
Sunil Shah
CEO & Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sunil Shah invest in?
Sunil Shah invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sunil Shah?
Public channels for Sunil Shah include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sunil Shah last invest?
The most recent investment recorded for Sunil Shah closed in Apr 2021. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
